BRAF and thyroid gland undifferentiated (anaplastic) carcinoma: Firstly, in 2018, Subbiah et al. published results regarding the activity of dabrafenib and trametinib in BRAF V600E-mutated anaplastic thyroid cancer (ATC) [97].